Skip to main content

Table 2 Clinical characteristics of the patients according to VAFmean at baseline and VAFmean-change

From: Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib

 

VAFmean at baseline

VAFmean-change

high (≥0.85%a)

low (< 0.85%a)

p

< 0

≥0

p

sex (female/male)

2/10

4/8

0.6404

5/12

1/5

1

age, median

74 (67–84)

71.5 (54–88)

0.5826

71 (58–84)

76 (68–88)

0.1825

ALBI Grade, G1/G2, n

5/7

4/8

1

6/11

3/3

0.643

TNM, n

 4b/other

7/5

6/6

1

10/7

3/3

1

 4/other

9/3

8/4

1

13/4

3/3

0.3185

T, n

 3 or 4/0–2

8/4

6/6

0.6802

10/7

4/2

1

 4/0–3

1/11

2/10

1

2/15

1/5

1

 M, 1/0, n

7/5

5/7

0.6843

9/8

3/3

1

 N, 1/0, n

3/9

4/8

1

5/12

1/5

1

 BCLC, B/C, n

3/9

4/8

1

4/13

3/3

0.3185

 AFP,median, ng/mL

5.05 (0.5–1085.9)

193 (0.5–14,240)

0.0463

29 (0.5–142,400)

8.1 (0.5–1998.6)

0.441

 DCP, median, mAU/mL

133.5 (13–37,535)

682 (14–16,575)

0.6033

143 (13–16,575)

1270.5 (27–37,535)

0.3627

 MVI, presence/absence, n

1/11

1/11

1

2/15

0/6

1

History of prior treatment (yes/no), n

 Systemic therapy

3/9

3/9

1

4/13

2/4

0.6322

 Catheter treatment

8/4

10/2

0.6404

13/4

4/2

0.6322

 Local therapy

9/3

8/4

1

12/5

4/2

1

 Radiation therapy

2/10

3/9

1

5/12

0/6

0.2725

  1. VAF variant allele frequency, ALBI Albumin-bilirubin, TNM Tumor, Node, Metastasis, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein, DCP des-gamma-carboxy pro- thrombin, MVI macroscopic portal vein invasion
  2. aThe cut-off value of VAFmean at baseline set to median